Díaz-Beyá M, Brunet S, Nomdedéu J, Cordeiro A, Tormo M, Escoda L, Ribera J M, Arnan M, Heras I, Gallardo D, Bargay J, Queipo de Llano M P, Salamero O, Martí J M, Sampol A, Pedro C, Hoyos M, Pratcorona M, Castellano J J, Nomdedeu M, Risueño R M, Sierra J, Monzó M, Navarro A, Esteve J
Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain.
Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Blood Cancer J. 2015 Oct 2;5(10):e352. doi: 10.1038/bcj.2015.76.
Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by cytogenetics and molecular profiling. In elderly patients (⩾60 years) with normal karyotype AML miR-3151 have been identified as a prognostic factor. However, miR-3151 prognostic value has not been examined in younger AML patients. In the present work, we have studied miR-3151 alone and in combination with BAALC, its host gene, in a cohort of 181 younger intermediate-risk AML (IR-AML) patients. Patients with higher expression of miR-3151 had shorter overall survival (P=0.0025), shorter leukemia-free survival (P=0.026) and higher cumulative incidence of relapse (P=0.082). Moreover, in the multivariate analysis miR-3151 emerged as independent prognostic marker in both the overall series and within the unfavorable molecular prognostic category. Interestingly, the combined determination of both miR-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers (P=0.003). In addition, we studied the microRNA expression profile associated with miR-3151 identifying a six-microRNA signature. In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML.
急性髓系白血病（AML）是一种异质性疾病，其预后主要与细胞遗传学和分子谱所赋予的生物学风险相关。在核型正常的老年（≥60岁）AML患者中，miR-3151已被确定为一种预后因素。然而，miR-3151的预后价值尚未在年轻AML患者中进行研究。在本研究中，我们在181例年轻的中危AML（IR-AML）患者队列中单独研究了miR-3151，并将其与宿主基因BAALC联合进行了研究。miR-3151表达较高的患者总生存期较短（P=0.0025），无白血病生存期较短（P=0.026），复发累积发生率较高（P=0.082）。此外，在多变量分析中，miR-3151在整个系列以及不良分子预后类别中均成为独立的预后标志物。有趣的是，miR-3151和BAALC的联合检测改善了这种预后分层，与那些一个或两个标志物水平升高的患者相比，两个参数水平均较低的患者预后更好（P=0.003）。此外，我们研究了与miR-3151相关的微小RNA表达谱，确定了一个由六个微小RNA组成的特征。总之，对miR-3151和BAALC表达的分析可能有助于改善年轻IR-AML患者的预后分层。
